Thanks to the incredible dedication of the entire Ocular Therapeutix team, along with our outstanding investigators and study sites, we’re thrilled to announce that the SOL-1 Phase 3 trial for OTX-TKI will complete randomization this week, with more than 300 patients now randomized. This milestone marks a significant step forward in advancing treatments for retinal diseases, and we couldn’t be more excited about the potential impact for patients. Read more here: https://ow.ly/fiYh50UjeIJ. #OCUTX #wetAMD #NPDR #RetinalDiseases
About us
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.
- Website
-
http://www.ocutx.com
External link for Ocular Therapeutix, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Bedford, MA
- Type
- Public Company
- Founded
- 2006
- Specialties
- ocular drug delivery, surgical sealants, sustained delivery, ophthalmic therapies, ophthalmology, optometry, retina, cataract, glaucoma, wet AMD, anti-vegf, and drug delivery
Locations
-
Primary
Get directions
15 Crosby Drive
Bedford, MA 01730, US
-
Get directions
36 Crosby Drive
Suite 101
Bedford, MA 01730, US
Employees at Ocular Therapeutix, Inc.
Updates
-
Wishing you a joyful and festive holiday season from the Ocular Therapeutix team! #OCUTX #HappyHolidays
-
-
Join the Ocular Therapeutix team! #NowHiring #MarketAccess #OCUTX Click here to view the full job description: https://ow.ly/lVJG50UuWmx Click here for a full list of open positions: https://ow.ly/n2iN50UuWmy
-
-
2024 has been an exciting year for Ocular Therapeutix! We have focused our efforts to become a leader in the retina space and create meaningful impact for patients living with retinal diseases. We’ve made significant progress advancing our registrational program for OTX-TKI in wet age-related macular degeneration and are grateful for the Ocular team and the retina community who have made these achievements possible. Hear more on what's next from Pravin Dugel, Executive Chairman, President and CEO. #OCUTX #RetinalDiseases #wetAMD #Retina
-
Join the Ocular Therapeutix team! #NowHiring #MarketAccess #OCUTX Click here to view the full job description: https://ow.ly/Pev150UqSO8 Click here for a full list of open positions: https://ow.ly/eehC50UqSO9
-
-
Many of us have loved ones who have been impacted by wet AMD, including Dean M. Donato, Director of Commercial Marketing at Ocular Therapeutix. It's patients like Dean's mother who inspire us to work towards advancing innovative treatment options for retinal diseases. Learn more at www.ocutx.com. #OCUTX #wetAMD #RetinalDiseases
-
-
We had an incredible experience at the FLORetina 12th International Congress in Florence, Italy! It was inspiring to hear world-renowned retina specialists share their insights on the future of retinal disease treatment. Thank you to everyone who attended our symposium and presentations. We look forward to seeing you all next year! #OCUTX #FLORetina2024 #wetAMD #NPDR #RetinalDiseases
-
-
We’re excited to announce that we’ll be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13th at 5:15 PM PT! Read more here: https://ow.ly/3r6t50UorPm. $OCUL #OCUTX #JPM2025 #RetinalDiseases #wetAMD #NPDR
-